AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
AUSTIN, Texas–(BUSINESS WIRE)—- $IPA #AI–ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs […]
‘Game changing’ fat jabs WON’T help you lose as much weight as you think, scientists discover
SO-CALLED “miracle” weight-loss jabs are far less effective in the real world than in clinical trials, a major study has revealed. The new findings could have big implications for Brits considering the injections, which have soared in popularity across the UK in recent years. AlamyIn a ‘real-world’ setting people might lose less weight in a […]
The Vibrating Belt Machine
I heard the discourse between Laraine and Christopher last night on the Downsized and I came across this article in the Business Insider today, and I just had to pass it on… Working out without working hard – the rise of Ozempic has Americans chasing dubious muscle-building miracles by Emily Steward June 12, 2025 in […]
Medical experts warn ‘Big Food’ is fighting back against Ozempic with addictive items for sale
Some medical experts warn that as Ozempic helps overcome food addiction, the junk food industry is adapting with ultraprocessed foods designed to hijack brain reward systems.
Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials
Abstract Aims Obesity is a major risk factor for heart failure with mildly reduced or preserved ejection fraction (HFpEF). This meta-analysis of randomised clinical trials (RCTs) evaluated the effects of incretin-based therapies (IBTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs, on clinical outcomes in individuals with the obesity-HFpEF phenotype. Materials and […]
Americans are obsessed with taking the ‘work’ out of working out
H. Armstrong Roberts/ClassicStock/Getty Images; BI Every generation has its own version of the vibrating belt machine — the ’50s-era contraption that promised to literally shake housewives into shape with minimal effort (and effect). This perpetual fitness obsession is why, on a recent Friday in June, I found myself strapped into the 2025 iteration: an electro-muscle […]
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
Abstract Basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are available in two fixed-ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide. FRCs offer a convenient strategy to administer basal insulin and a GLP-1 RA, taking advantage of complementary mechanisms in a single […]
The weight loss drug Mounjaro has been approved to treat sleep apnoea. How does it work?
coldsnowstorm/Getty Images Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a condition in which breathing stops and starts repeatedly during sleep. The TGA has indicated Mounjaro can be used to treat moderate to severe obstructive sleep apnoea in adults with obesity (a body-mass index of 30 or […]
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a […]